Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice

Table 2 Patient population baseline demographics

Parameter		Frequency	Relative percentage (%)
Patient demographic
Gender	Male	206	51.5
	Female	194	48.5
Age	Median	67.7 yr
	Range	29.9-94.2
Comorbidity grade (according to Adult Comorbidity Evaluation-27)[34]	None	149	37.32
	Mild	164	412
	Moderate	60	152
	Severe	27	6.82
Pathological confirmation of malignancy	Yes	355	88.82
	No1	45	11.32
Stage	Localised (I-II)	4	1.0
	Locally advanced (III)	202	50.5
	Metastatic (IV)	194	48.5
Eastern Cooperative Oncology Group Performance Status at time of PDAC diagnosis	0	43	10.82
	1	198	49.52
	2	98	24.52
	3	58	14.52
	4	3	0.82
Treatment characteristics
Treatment intent at time of referral3	Curative	62	15.5
	Palliative	338	84.5
Curative management
Patient received curative surgery?	Yes	65	16.3
Patient received adjuvant chemotherapy after curative surgery	Yes	42	65.6
	No	22	34.4
	Unknown	1	n/a
Type of adjuvant chemotherapy	5-fluorouracil	1	2.42
	Capecitabine	18	42.92
	Gemcitabine	23	54.82
Palliative management
Patient received palliative chemotherapy	Yes	230	57.5
	No	170	42.5
Type of palliative chemotherapy	FOLFIRINOX	37	16.1
	Gemcitabine/Capecitabine	60	26.1
	Gemcitabine/Cisplatin	5	2.2
	Gemcitabine NabPaclitaxel	27	11.7
	Gemcitabine monotherapy	94	40.9
	Other4	7	3.0

¹Refers to patients diagnosed based on clinical and radiological data only following agreement in multidisciplinary team discussion.

²Indicates rounding error.

³Curative treatment intent refers to patients treated with curative surgery (number of patients with curative surgery and number of patients treated with curative intent do not match due to some patients being referred to our centre for consideration of palliative treatment at time of tumour relapse following curative surgery) (3 patients).

⁴Other include: 5FU/oxaliplatin: 3 patients; Gemcitabine + TH-302/placebo: 2 patients; Gemcitabine plus vandetanib/placebo: 1 patient; Capecitabine single agent: 1 patient.

n/a: Not applicable; PDAC: Pancreatic ductal adenocarcinoma; FOLFIRINOX: Folinic acid, 5-fluorouracil (5FU), irinotecan, oxaliplatin; yr: Years.